Novo Nordisk Stock Rises as Q4 Wegovy Sales More Than Double
Novo Nordisk's U.S.-listed shares rose 5% in intraday trading after the Ozempic and Wegovy maker's better-than-estimated ...
Novo Nordisk Annual Sales Jump on Higher Demand for Obesity Drugs
The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...
Novo Nordisk missed its diversity targets last year, and its CEO paid a financial price
Novo Nordisk's CEO took a $1.5 million pay cut in 2024 as the pharma giant's share price tanked and it missed profit and DEI ...
Wegovy maker Novo Nordisk says surging growth driving emissions higher
Novo Nordisk emissions grew 23% in 2024, the company said on Wednesday, and will keep rising through the end of the decade as ...
Inc9d
Novo Nordisk Foundation Will Not Fill Funding Gaps
LONDON (Reuters) – The Novo Nordisk Foundation does not plan to step in to prop up a global health sector reeling from a ...
Novo Nordisk's next-gen obesity drug Cagrisema: investors seek answers
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
This is Money6d
Novo Nordisk cashes in on obesity and diabetes drugs as profits swell
Novo Nordisk has achieved another blockbuster financial year as the group cheered intense global demand for its obesity and diabetes drugs. The Danish pharmaceutical giant reported turnover from ...